Wholesale
Wholesale pricing available
Qualify for automatic discounts at checkout when your order of wholesale eligible items hits a volume threshold.
$2,000+15% off$4,000+20% off$6,000+25% off$10,000+40% offFull wholesale details →
$315.00$350.00
($63.00 / Item) — Save $35.00 (10% off)
In stock — dispatches within 24h, tracked
ARA-290 10mg. Used to support nerve health, tissue repair, reduced inflammation, and recovery. Lab tested, discreetly shipped across Canada.
FormatLyophilized Vial
ConcentrationDependent on reconstitution with BAC water
Package Selected: 5 Pack Special
Pay with Interac e-Transfer or Crypto
Wholesale pricingCost per item by order value
$2,000+15% off$267.75per item
$4,000+20% off$252.00per item
$6,000+25% off$236.25per item
$10,000+40% off$189.00per item
Estimated prices based on the current product or selected option price. Tiers use your eligible wholesale subtotal before the wholesale discount. Discounts apply automatically in your cart.
Choose an option to see its wholesale prices.
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
ARA-290 is a synthetic 11-amino acid peptide derived from the helix B surface of erythropoietin (EPO) specifically engineered to selectively activate the innate repair receptor (IRR) while eliminating the erythropoietic and thrombotic activity associated with full length EPO administration. Hudson Science’s formulation supplies 10mg as a lyophilized vial, preserving peptide structural integrity and potency across storage conditions until reconstitution. Standard practice for synthetic peptides of this class where aqueous stability at ambient temperature is limited.
The structural engineering behind ARA-290 is its defining research characteristic. Full length erythropoietin activates two distinct receptor systems; the classical EPO receptor homodimer driving red blood cell production and platelet activity, and the tissue protective innate repair receptor heterodimer mediating cytoprotective and anti inflammatory responses in non hematopoietic tissue. ARA-290’s design isolates the helix B sequence responsible for IRR binding while eliminating the receptor binding domains associated with erythropoietic activity producing a compound with selective tissue protective and anti inflammatory signaling activity uncoupled from the hematopoietic and cardiovascular risks associated with EPO administration. This receptor selectivity makes ARA-290 a uniquely valuable research tool for studying EPO’s cytoprotective mechanisms in isolation from its erythropoietic activity.
ARA-290’s research literature spans several clinically relevant areas where IRR mediated tissue protection has been investigated. Neuropathic pain modulation has been a primary research focus. ARA-290 has been studied in clinical trials examining painful diabetic neuropathy, with documented effects on small nerve fiber regeneration and inflammatory cytokine reduction in affected tissue. Additional documented research areas include pancreatic beta cell protection, wound healing, and systemic inflammation modulation; a diverse tissue protective research profile that reflects the broad distribution of IRR receptors across multiple organ systems and the growing research interest in EPO derived tissue protection peptides as a distinct compound class from erythropoietic agents.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and Hudson Science’s ARA-290 meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside BPC-157 and TB-500 in comparative tissue protection and anti inflammatory peptide studies. Browse CSD’s full peptide range for complete sourcing.
ARA-290, also known as cibinetide or pHBSP, is a synthetic 11-amino-acid peptide derived from the helix B surface of erythropoietin (EPO). It was engineered to reproduce EPO associated tissue protective and anti inflammatory signaling without stimulating the classical erythropoietic pathway responsible for red blood cell production. This product contains 10mg of lyophilized ARA-290 in a single vial for laboratory research.
ARA-290 has been investigated primarily in neurological, inflammatory, and tissue repair research. Human and preclinical studies have examined small fiber neuropathy, neuropathic pain, corneal nerve regeneration, inflammatory signaling, neuronal protection, and tissue recovery following injury. Research has been particularly focused on conditions involving damaged peripheral nerves and impaired small nerve fiber function.
ARA-290 was designed to activate the tissue protective signaling pathway associated with the innate repair receptor, a receptor complex involving the erythropoietin receptor and the beta common receptor CD131. Activation of this pathway has been studied for anti inflammatory, anti apoptotic, neuroprotective, and tissue repair effects. Unlike erythropoietin itself, ARA-290 was specifically engineered to avoid significant activation of the classical receptor pathway responsible for erythropoiesis.
Small fiber neuropathy involves damage to small sensory and autonomic nerve fibers and can produce neuropathic pain and altered sensory function. Clinical research with ARA-290 has reported changes in measures such as corneal nerve fiber density, sensory pain thresholds, and patient reported functional outcomes. These findings have made nerve regeneration and small fiber neuropathy some of the most extensively studied human research applications for cibinetide.
Yes! This batch is HPLC tested to verify ARA-290 identity and content accuracy at 10mg per vial. A certificate of analysis is available.
